NCT02946762

TasP in Correctional Facilities

Completed NA Last updated 13 March 2019

What this trial tests

NA trial testing Test and treat in HIV in 419 participants. Completed in 31 March 2018.

Timeline

1 February 2016

Primary endpoint
31 March 2018

31 March 2018

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	419
Start date	1 February 2016
Primary completion	31 March 2018
Estimated completion	31 March 2018
Sites	1 location across Zambia

Drugs / interventions tested

• Test and treat

Conditions studied

• HIV — all drugs for HIV →
• Tuberculosis — all drugs for Tuberculosis →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with HIV or Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

At correctional facilities in Zambia and South Africa, a cross-sectional study design will be used to characterize the full continuum of integrated HIV/TB care under Treatment as Prevention (TasP), and will enrich this approach by: 1) using individual-level cohort data for HIV-infected inmates to assess ART uptake under TasP/Universal Test and Treat (UTT), as well as 6-month virological suppression and retention in care for inmates initiating ART; and 2) mixed methods to identify health-system, corrections-related socio-cultural and individual-inmate barriers to and facilitators of TasP/UTT to refine TasP implementation; and 3) conducting a retrospective chart review using routine data from Ministry of Health registers to reconstruct an approximate HIV and TB cascade for all inmates (HIV-infected and HIV-uninfected) at 3 and 12 months into TasP/UTT implementation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study.
   Herce ME, Hoffmann CJ, Fielding K, Topp SM, et al · · 2020 · cited 23× · PMID 32763152 · DOI 10.1016/s2352-3018(20)30188-0
2. Delivery of TB preventive therapy to incarcerated people living with HIV in southern African correctional facilities.
   Chimoyi L, Smith H, Hausler H, Fielding K, et al · · 2021 · cited 1× · PMID 34956843 · DOI 10.5588/pha.21.0056